EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022

Printer-friendly versionPDF version

This report provides an overview of the risk factors and global trends of HIV in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging markets—Brazil, India, and China.

(PressReleasePoint) -
Although the number of HIV incident cases is expected to drop across the majority of Europe’s major nations in the near future, the UK figure will actually increase, predicts research and consulting firm GlobalData.
 
According to the London based company’s new epidemiology report*, the number of newly diagnosed HIV cases in the UK is forecast to climb from 7,545 in 2012 to 8,691 by the end of 2022 – representing an increase of 15%.
 
The rise runs counter to forecasted trends for other major EU nations such as Germany, Italy, France and Spain, who can all expect falling incident cases of HIV during the same period, says GlobalData.
 
Due primarily to substantial population growth within the 15–49 years age group, GlobalData expects India to have the highest increase in HIV incident cases, with an increase of over 21,000 new cases expected over the 10 years.
 
For Sample Pages, please click or add the below link to the browser:
http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/human-immunodeficiency-virus-epidemiology-forecast-to-2022/sample&CompanyID=prpoi
 
Alyssa Klein, GlobalData’s Senior Analyst covering Epidemiology, says: “If India and China adopt prevention programs similar to Brazil, which is often considered a model of HIV prevention for the developing world, the number of incident cases could decrease, as high-risk groups become the focus of targeted prevention strategies.”
 
Of the 10 markets studied in the report, Japan is expected to display the highest growth rate for the next decade. Although the country displayed the lowest number of HIV prevalent cases in 2012, with 1,327, this figure is forecast to climb by almost 40% to 1,854 by 2022.
 
This report provides an overview of the risk factors and global trends of HIV in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging markets—Brazil, India, and China.
 
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
 
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
 
For further details, please click or add the below link to the browser:
http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/human-immunodeficiency-virus-epidemiology-forecast-to-2022&CompanyID=prpoi
 
Visit report store: http://www.globaldata.com/reportstore
 
For more details contact:
pressreleases@globaldata.com
            
North America:                 +1 646 395 5477
Europe:                                +44 207 753 4299
                                                +44 1204 543 533
Asia Pacific:                         +91 40 6616 6782